Gilead Sciences, Inc. (GILD)
NASDAQ • Healthcare
July 7, 2026 at 14:31 UTC
About Gilead Sciences, Inc.
Gilead Sciences, Inc. discovers, develops, and commercializes medicines for critical health needs and trades on the NASDAQ as GILD. The biopharmaceutical company sits in healthcare, with FY2025 revenue of $29.4 billion, and its portfolio spans antiviral therapies, oncology and cell therapy products, and specialty cardiovascular treatments.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Gilead Sciences, Inc.'s Technical Indicators Summary
GILD shows a buy-oriented technical set characterized by broad moving-average support and strong momentum readings in some oscillators, yet with mixed shorter-term signals. Price is above several key averages including the 200-day, MACD and momentum readings are constructive, and OBV indicates accumulation. However, the stock is extended relative to the Bollinger upper band and a longer-term moving average sits above the market, tempering the near-term picture. Volatility is subdued and ADX is low, so trend conviction is limited. Technical takeaway: Buy — underlying trend and accumulation favor the upside despite short-term stretch.
| Indicator | Value |
|---|---|
RSI (14) | 61.85 |
Stochastic %K (14, 3, 3) | 85.31 |
CCI (20) | 280.19 |
WPR (14) | -9.40 |
Momentum (10) | 9.55 |
MFI | 65.03 |
MACD Level (12, 26) | 0.09 |
Bollinger Bands | $120.69 - $132.11 |
ATR (14) | $3.80 (2.83%) |
ADX (14) | 15.89 |
OBV | 67,032,458 |
Classic Pivot Point | $130.12 |
Fibonacci Pivot Point | $130.12 |
Simple Moving Averages | $126.40 - $136.37(5 indicators) |
Exponential Moving Averages | $127.39 - $131.50(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
A mild wave of selling in the last session saw GILD edge lower to 131.27, off -1.26% from the previous day. GILD retreats as RBC lowers its price target, keeping a sector Perform rating.
Trading Volume
0
vs S&P 500 Today
Underperforming Market
-2.38%
52-Week Position
Mid-range
44.1%
Updated: July 7, 2026 at 12:10 UTC
Quote Summary
GILD Headlines
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Biotech, Pharma Stocks Draw Fresh Valuation Focus
April 2, 2026
Gilead to buy Ouro, plan Galapagos tie-up
March 23, 2026
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
March 15, 2026